{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T14:10:54Z","timestamp":1777558254616,"version":"3.51.4"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"26","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Apatinib is an oral small-molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2). Some clinical trials have demonstrated that apatinib is efficacious against advanced nonsquamous NSCLC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>This study aimed to probe efficacy and safety of apatinib plus docetaxel, as the second or above line treatment, in advanced nonsquamous NSCLC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design:<\/jats:title>\n            <jats:p>Multicenter, prospective, single arm study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Setting:<\/jats:title>\n            <jats:p>Three teaching hospitals centers in the Sichuan.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Participants:<\/jats:title>\n            <jats:p>Fourteen patients with stage IVA\/B nonsquamous NSCLC had previously received at least 1 platinum-based chemotherapy regimen.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Intervention:<\/jats:title>\n            <jats:p>Patients who were enrolled between November 2016 and January 2018 were given docetaxel (75\u200amg\/m<jats:sup>2<\/jats:sup>, i.v., d1) plus oral apatinib (250\u200amg\/d), 4 weeks as one cycle, until disease progression or intolerance to adverse events (AE).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Main outcome measures:<\/jats:title>\n            <jats:p>The primary endpoint was progression-free survival (PFS). The secondary endpoints comprised objective response rate (ORR), disease control rate (DCR), overall survival (OS), and AE incidence rate.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>All patients carried adenocarcinoma by pathological type. The median follow-up duration was 9.76 months. Out of 14 cases, 12 were evaluable, showing ORR of 33.33%, DCR of 66.67%, DCR of 50% in cases with brain metastasis, median PFS of 2.92 months (95% CI: 1.38\u20134.48), and 6-month OS of 80%. Primary AEs encompassed: leukopenia in 7 cases (58.33%), hand-foot skin reaction in 5 cases (41.67%), and diarrhea in 4 cases (33.33%). Among them, grade 3 AEs were: leukopenia in 4 cases (33.33%), and hand-foot skin reaction in 1 case (8.33%). No grade 4\/5 AEs were reported. Univariate and multivariate analysis were conducted respectively for PFS and OS. These factors encompassed: gender, age, gene mutations, clinical stage, ECOG scores, quantity of metastatic foci, brain metastasis, and hand-foot skin reaction. Results demonstrated zero risk factors for PFS or OS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Apatinib plus docetaxel, as the second or above line treatment, is effective and safe against advanced nonsquamous NSCLC, with good tolerance profile.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration:<\/jats:title>\n            <jats:p>NCT03416231.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000016065","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T13:22:52Z","timestamp":1561728172000},"page":"e16065","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC"],"prefix":"10.1097","volume":"98","author":[{"given":"Qian","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of North Sichuan Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning-Ling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of North Sichuan Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai-Yuan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of North Sichuan Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bang-Xian","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of North Sichuan Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Central Hospital of Nanchong, Nanchong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-Dong","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Central Hospital of Dazhou, Dazhou, PR China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230914","first-page":"1","article-title":"Cancer statistics: updated cancer burden in China","volume":"27","author":"Chen","year":"2015","journal-title":"Chin J Cancer Res"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14656566.2015.1040391","article-title":"Emerging paradigms in targeted treatments for Asian patients with NSCLC","volume":"16","author":"Ke","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"issue":"(Suppl 1)","key":"R4-20230914","doi-asserted-by":"crossref","first-page":"S605","DOI":"10.1007\/s12032-010-9753-3","article-title":"Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patients","volume":"28","author":"Song","year":"2011","journal-title":"Med Oncol"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1097\/JTO.0b013e3181bbf223","article-title":"Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice","volume":"4","author":"Girard","year":"2009","journal-title":"J Thorac Oncol"},{"key":"R6-20230914","first-page":"856","article-title":"Retreatment with pemetrexed chemotherapy in advanced non-small cell lung cancer patient","volume":"6","author":"Song","year":"2014","journal-title":"J Thorac Dis"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.pharmthera.2004.01.002","article-title":"Signaling through the epidermal growth factor receptor during the development of malignancy","volume":"102","author":"Grandis","year":"2004","journal-title":"Pharmacol Ther"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2006.06.3958","article-title":"Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer","volume":"24","author":"Hirsch","year":"2006","journal-title":"J Clin Oncol"},{"issue":"(Suppl 1)","key":"R9-20230914","first-page":"e12","article-title":"A meta-analysis of erlotinib versus docetaxel for advanced nonsmall-cell lung cancer with poor prognosis","volume":"52","author":"Xu","year":"2015","journal-title":"Indian J Cancer"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1002\/cncr.31313","article-title":"Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: results from the US IRESSA Clinical Access Program (ICAP)","volume":"124","author":"Hirsch","year":"2018","journal-title":"Cancer"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2147\/OTT.S157755","article-title":"The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective analysis","volume":"11","author":"Wang","year":"2018","journal-title":"Onco Targets Ther"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s12885-018-4303-z","article-title":"Apatinib for advanced sarcoma: results from multiple institutions\u2019 off-label use in China","volume":"18","author":"Xie","year":"2018","journal-title":"BMC Cancer"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/jcrt.JCRT_258_17","article-title":"Apatinib for advanced nonsmall-cell lung cancer: a retrospective case series analysis","volume":"14","author":"Yang","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/ajco.12870","article-title":"Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: apatinib treatment in nonsquamous NSCLC","volume":"14","author":"Wu","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4103\/ijc.IJC_379_17","article-title":"Short-term efficacy and safety of apatinib in advanced squamous cell carcinoma of the lung","volume":"54","author":"Li","year":"2017","journal-title":"Indian J Cancer"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1200\/JCO.2008.18.7658","article-title":"First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy","volume":"27","author":"Inoue","year":"2009","journal-title":"J Clin Oncol"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J Clin Oncol"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.2147\/OTT.S113435","article-title":"Salvage treatment with apatinib for advanced non-small-cell lung cancer","volume":"10","author":"Song","year":"2017","journal-title":"Onco Targets Ther"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/362841a0","article-title":"Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo","volume":"362","author":"Kim","year":"1993","journal-title":"Nature"},{"key":"R21-20230914","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041176","article-title":"Tumor-associated macrophages and mast cells positive to tryptase are correlated with angiogenesis in surgically-treated gastric cancer patients","volume":"19","author":"Sammarco","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.lungcan.2005.09.005","article-title":"Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood","volume":"51","author":"Bremnes","year":"2006","journal-title":"Lung Cancer"},{"key":"R23-20230914","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.yexcr.2018.02.005","article-title":"Paracrine signaling by VEGF-C promotes non-small cell lung cancer cell metastasis via recruitment of tumor-associated macrophages","volume":"364","author":"Deng","year":"2018","journal-title":"Exp Cell Res"},{"key":"R24-20230914","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1349-7006.2011.01939.x","article-title":"YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo","volume":"102","author":"Tian","year":"2011","journal-title":"Cancer Sci"},{"key":"R25-20230914","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/acs.jmedchem.7b01091","article-title":"Discovery of novel potent VEGFR-2 inhibitors exerting significant antiproliferative activity against cancer cell lines","volume":"61","author":"Zhang","year":"2018","journal-title":"J Med Chem"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.bcp.2011.12.007","article-title":"Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells","volume":"83","author":"Tong","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"R27-20230914","doi-asserted-by":"crossref","first-page":"7981","DOI":"10.1158\/0008-5472.CAN-10-0111","article-title":"Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters","volume":"70","author":"Mi","year":"2010","journal-title":"Cancer Res"},{"key":"R28-20230914","first-page":"560","article-title":"Experiment of different administration sequences of apatinib and paclitaxel on lung cancer","author":"Wang","year":"2016","journal-title":"Cancer Res Prev Treat"},{"key":"R29-20230914","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","article-title":"Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study","volume":"15","author":"Seto","year":"2014","journal-title":"Lancet Oncol"},{"key":"R30-20230914","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejca.2017.07.037","article-title":"Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance","volume":"84","author":"Li","year":"2017","journal-title":"Eur J Cancer"},{"key":"R31-20230914","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase iii trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J Clin Oncol"},{"key":"R32-20230914","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-017-0521-0","article-title":"Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study","volume":"10","author":"Liu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"R33-20230914","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/ajco.12834","article-title":"Clinical response to apatinib monotherapy in advanced non-small cell lung cancer","volume":"14","author":"Xu","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"R34-20230914","doi-asserted-by":"crossref","first-page":"e9053","DOI":"10.1097\/MD.0000000000009053","article-title":"A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial\/Experimental Study","volume":"96","author":"Wang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R35-20230914","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/micc.12103","article-title":"The dynamic changes of capillary permeability and upregulation of VEGF in rats following radiation-induced brain injury","volume":"21","author":"Jin","year":"2014","journal-title":"Microcirculation"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201906280-00025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T22:14:20Z","timestamp":1694729660000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201906280-00025"}},"subtitle":["A multi center prospective study"],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":35,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000016065","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}